First Discussion Opportunity for EC Pharmaceutical Package
A New Vision for the Pharmaceutical Sector-First Discussion Opportunity for European Commission Pharmaceutical Package
Brussels- The first in-depth opportunity to understand, debate and influence new European Commission (EC) legislative changes and their implications-the Proposals for new Pharmaceutical Legislation EU update meeting-is being hosted by The Organisation for Professionals in Regulatory Affairs (TOPRA) on 25-26 February 2009.
Over the two days of this meeting nearly 20 speakers from the European Commission, pan-European national agencies, national authorities and industry will discuss the European Pharmaceutical Package announced by the European Commission on 10th December 2008 and give their view on the new legislation proposals.
Issues discussed at the conference will include the development, purpose and expected outcomes of the pharmaceutical package, counterfeit medicines, information to patients and pharmacovigilance. Please find
attached the draft programme which gives further detail.
This conference has relevance for all of industry, health agencies and other stakeholders. It should be attended by anyone that the 'Pharma Package' will affect.
The organisers would like to take this opportunity to invite you to conference and take advantage of a number of free press passes that are available.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
